A Phase III Randomized Double-blind Study of Pembrolizumab Plus Best Supportive Care vs. Placebo Plus Best Supportive Care as Second-Line Therapy in Asian Subjects With Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-394)
Phase of Trial: Phase III
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-394
- Sponsors Merck Sharp & Dohme
- 08 May 2017 Status changed from not yet recruiting to recruiting.
- 31 Mar 2017 Planned End Date changed from 1 Sep 2019 to 23 Dec 2019.
- 31 Mar 2017 Planned primary completion date changed from 1 Sep 2019 to 23 Dec 2019.